Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis
In a Chinese healthcare context, modified gemcitabine coupled with oxaliplatin (mGEMOX) is not a cost-effective treatment option for unresectable GBC.
Authors
- Fangyuan Tian
- Zhaoyan Chen (ORCID: https://orcid.org/0000-0002-0181-1564)
Institutions
- Sichuan University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3389/fpubh.2024.1432947
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sichuan University
- West China Hospital, Sichuan University